UBS Maintains Buy on AdaptHealth, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Whit Mayo has maintained a Buy rating on AdaptHealth (NASDAQ:AHCO) and increased the price target from $9 to $13.
February 28, 2024 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Whit Mayo has reaffirmed a Buy rating on AdaptHealth and raised the price target from $9 to $13.
The increase in price target by a reputable analyst like Whit Mayo suggests a strong confidence in AdaptHealth's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100